Source-grounded facts extracted from CATALYST PHARMACEUTICALS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CATALYST PHARMACEUTICALS, INC.: Amended Article VIII, Section 8.1 of the By-Laws (Forum Selection Amendment) (effective 2026-05-06).
“On May 6, 2026, the Board of Directors approved and adopted an amendment (the “ Forum Selection Amendment ”) to the Company’s existing By-Laws that amends Article VIII, Section 8.1 of the By-Laws of the Company.”
CATALYST PHARMACEUTICALS, INC. entered into Agreement and Plan of Merger with Angelini Pharma S.p.A. valued at $31.50 per Share in cash (effective 2026-05-06).
“On May 6, 2026, Catalyst Pharmaceuticals, Inc. (“ Catalyst ” or the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Angelini Pharma S.p.A., an Italian Società per azioni (“ Angelini Pharma ” or “ Parent ”), and Angelini Cielo Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“ Merger Sub ”), providing for the merger of Merger Sub with and into the Company (the “ Merger ”), with the Company surviving the Merger as a wholly-owned subsidiary of Parent.”
Charles B. O'Keeffe departed as Director at CATALYST PHARMACEUTICALS, INC..
“As previously reported, Charles B. O’Keeffe, an independent member of the Board, did not stand for re-election at the Annual Meeting.”
Charles B. O’Keeffe departed as Lead Independent Director at CATALYST PHARMACEUTICALS, INC..
“On January 17, 2025, Charles B. O’Keeffe, an independent member of the Board of Directors (“Board”) of Catalyst Pharmaceuticals, Inc. (the “Company”), advised the Company of his decision to not stand for reelection at the 2025 annual meeting of the Company’s stockholders.”
CATALYST PHARMACEUTICALS, INC. entered into Underwriting Agreement with BofA Securities, Inc. and Citigroup Global Markets, Inc., as representatives of the underwriters named in Schedule A to the Underwriting Agreement valued at 10,000,000 shares of the Company’s common stock, par value $0.001 per share, at a public offering pr (effective 2024-01-04).
“On January 4, 2024, Catalyst Pharmaceuticals, Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with BofA Securities, Inc. and Citigroup Global Markets, Inc., as representatives of the underwriters named in Schedule A to the Underwriting Agreement (collectively, the “ Underwriters ”), relating to the public offering, issuance and sale (the “ Offering ”) by the Company of 10,000,000 shares of the Company’s common stock, par value $0.001 per share (the “ Shares ”), at a public offering price of $15.00 per share, less underwriting discounts”
Jeffrey Del Carmen changed role as Executive Vice President, Chief Commercial Officer at CATALYST PHARMACEUTICALS, INC..
“and of Jeffrey Del Carmen to Executive Vice President, Chief Commercial Officer”
Steven Miller changed role as Executive Vice President, Chief Operating and Scientific Officer at CATALYST PHARMACEUTICALS, INC..
“the Company reported the promotion, effective on January 1, 2024, of Dr. Steven Miller to Executive Vice President, Chief Operating and Scientific Officer”
Michael W. Kalb was appointed as Executive Vice President and Chief Financial Officer at CATALYST PHARMACEUTICALS, INC..
“On December 4, 2023, the Company announced the appointment of Michael W. Kalb as the Company's Executive Vice President and CFO, effective January 1, 2024.”
Alicia Grande retired as Chief Financial Officer at CATALYST PHARMACEUTICALS, INC..
“On December 1, 2023, Alicia Grande, the Chief Financial Officer ("CFO") of Catalyst Pharmaceuticals, Inc. (the " Company ") informed the Company of her intent to retire as the Company's CFO at the end of 2023.”
Richard J. Daly was appointed as Chief Executive Officer at CATALYST PHARMACEUTICALS, INC..
“the appointment of Richard J. Daly, 62, as its Chief Executive Officer (“ CEO ”), to become effective on January 1, 2024.”
Patrick J. McEnany retired as Chairman of the Board at CATALYST PHARMACEUTICALS, INC..
“The Company’s current CEO, Patrick J. McEnany, will continue to serve as the Company’s CEO until December 31, 2023 and, following his retirement as the Company’s CEO, will continue to serve on the Company’s Board of Directors (“ Board ”) as the non-executive Chairman of the Board.”
Philip H. Coelho retired as Director at CATALYST PHARMACEUTICALS, INC..
“Philip H. Coelho, an independent member of the Board, did not stand for re-election at the Annual Meeting.”
Patrick J. McEnany retired as Chief Executive Officer at CATALYST PHARMACEUTICALS, INC..
“On July 24, 2023, Patrick J. McEnany, the Company’s Chief Executive Officer (“CEO”), informed the Company’s Board of Directors that he intends to retire as the Company’s CEO by the end of 2023.”
CATALYST PHARMACEUTICALS, INC. completed an acquisition involving Santhera Pharmaceuticals Holdings AG for all-cash purchase payment of $75 million; strategic equity investment of approximately $15 million in Santhera ordinary shares; potential milestone payments and (closed 2023-07-19).
“Item 2.01 Completion of Acquisition or Disposition of Assets On July 19, 2023, Catalyst Pharmaceuticals, Inc. (the “ Company ”) completed its acquisition from Santhera Pharmaceuticals Holdings AG (“ Santhera ”) of an exclusive license for North America for vamorolone, a potential treatment for patients suffering with Duchenne Muscular Dystrophy (“ DMD ”). The license is for exclusive commercial rights in the U.S., Canada, and Mexico, as well as the right of first negotiation in Europe and Japan should Santhera pursue partnership opportunities. Additionally, the Company will hold North American rights for any future approved indications of vamorolone. As previously disclosed, the Company will make an all-cash purchase payment of $75 million to acquire the license pursuant to a License Agreement, dated June 19, 2023, by and between Santhera, its wholly owned subsidiary, Santhera Pharmaceuticals (Schweiz) AG, and the Company (the “ License Agreement ”). Simultaneously, pursuant to an Inve”
CATALYST PHARMACEUTICALS, INC. entered into Investment Agreement with Santhera Pharmaceuticals Holding AG valued at $15,000,000 investment at CHF 0.9477 per share (effective 2023-06-19).
“Additionally, pursuant to the terms of the Investment Agreement, the Company will make a $15 million investment into Santhera at a price of CHF 0.9477 ($1.08 USD) per share, a mutually agreed upon volume-weighted average price prior to signing, with the investment proceeds to be used by Santhera for Phase IV studies in DMD and further development of additional indications.”
CATALYST PHARMACEUTICALS, INC. entered into License and Collaboration Agreement with Santhera Pharmaceuticals Holding AG valued at $75,000,000 upfront payment (effective 2023-06-19).
“On June 19, 2023, Catalyst Pharmaceuticals, Inc. (the “ Company ”) entered into a License and Collaboration Agreement (the “ License Agreement ”) and an Investment Agreement (the “ Investment Agreement ”, and together with the License Agreement, the “ Agreements ”)) with Santhera Pharmaceuticals Holding AG (“ Santhera ”), under which the Company will enter into an exclusive North America license, manufacturing and supply agreement for Santhera’s investigational product candidate, vamorolone, a dissociative steroid currently under FDA review for the treatment of Duchenne Muscular Dystrophy (“ DMD ”).”
Tamar Thompson was appointed as Director at CATALYST PHARMACEUTICALS, INC..
“has appointed Tamar Thompson to the Board.”
Philip H. Coelho retired as Director at CATALYST PHARMACEUTICALS, INC..
“On March 29, 2023, Philip H. Coelho, an independent member of the Board of Directors (“Board”) of Catalyst Pharmaceuticals, Inc. (the “Company”), advised the Company of his decision not to stand for reelection at the 2023 annual meeting of the Company’s stockholders.”
CATALYST PHARMACEUTICALS, INC. completed an acquisition involving Eisai Co., Ltd. for $160 million (closed 2023-01-24).
“Asset Purchase Agreement (the “ Purchase Agreement ”) between the Company and Eisai. Under the terms of the Purchase Agreement, the Company paid an upfront payment to Eisai of $160 million. Also at the closing of the asset purchase, the parties entered into two related agreements: (i) a short term Transition Services Agreement (the “ Transition Services Agreement”
CATALYST PHARMACEUTICALS, INC. entered into Asset Purchase Agreement with Eisai Co., Ltd valued at $160 million (effective 2022-12-17).
“On December 17, 2022, Catalyst Pharmaceuticals, Inc. (the “ Company ”) entered into an Asset Purchase Agreement (the “ Purchase Agreement ”) with Eisai Co., Ltd (“ Eisai ”), pursuant to which the Company has agreed to acquire from Eisai the U.S. rights for FYCOMPA ® (perampanel) CIII.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.